Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
All content for Evaluating Biopharma is the property of Evaluating Biopharma and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
Episode: 15 - Facing CMC Challenges in CDMO-Sponsor Relationships for Rare Disease Platforms with Nesredin Mussa
Evaluating Biopharma
19 minutes
1 year ago
Episode: 15 - Facing CMC Challenges in CDMO-Sponsor Relationships for Rare Disease Platforms with Nesredin Mussa
In this month’s episode of Evaluating Biopharma, host Ben Locwin speaks with Nesredin Mussa, PhD, president of Dynamica Biologics, about navigating the challenges of securing successful CDMO-sponsor relationships for a rare disease manufacturing and testing paradigm, the key contributing factors that may pose within the partnership between the sponsor and CDMO, and how small companies can manage with the enhanced regulatory demands due to the nascent nature of these particular therapeutic pla...
Evaluating Biopharma
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
